First Inhaled COPD Therapy In Over 2 Decades - FDA Approves Verona Pharma's First Commercial Product
Benzinga • 599 days
Low Materiality0/10
Information
On Wednesday, the FDA approved Verona Pharma plc's VRNA Ohtuvayre (ensifentrine) for the maintenance...
Original sourceAI Summary
- FDA approved VRNA's Ohtuvayre for COPD maintenance treatment. - Ohtuvayre combines bronchodilator and anti-inflammatory effects in one molecule. - Drug expected to generate $3.6 billion in peak sales. - Price Impact Rating: Bullish - Impact Horizon Rating: Short-term - Type: Corporate Developments
Market-Moving
- FDA approved VRNA's Ohtuvayre for COPD maintenance treatment.
- Ohtuvayre combines bronchodilator and anti-inflammatory effects in one molecule.
- Drug expected to generate $3.6 billion in peak sales.
Key Facts
- FDA approved VRNA's Ohtuvayre for COPD maintenance treatment.
- Ohtuvayre combines bronchodilator and anti-inflammatory effects in one molecule.
- Drug expected to generate $3.6 billion in peak sales.